228 related articles for article (PubMed ID: 24726076)
1. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.
Hasan H; Howard F; Morgan SG; Metzger DL; Lo AC; Goddard K; Gill S; Johnson M
Healthc Policy; 2014 Feb; 9(3):80-96. PubMed ID: 24726076
[TBL] [Abstract][Full Text] [Related]
2. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
McLeod L; Bereza BG; Shim M; Grootendorst P
Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
[TBL] [Abstract][Full Text] [Related]
3. Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.
Knowles SR; Lee K; Paterson JM; Shah BR; Mamdani MM; Juurlink DN; Gomes T
Can J Diabetes; 2017 Apr; 41(2):138-142. PubMed ID: 27989494
[TBL] [Abstract][Full Text] [Related]
4. Public drug plan coverage for children across Canada: a portrait of too many colours.
Ungar WJ; Witkos M
Healthc Policy; 2005 Sep; 1(1):100-22. PubMed ID: 19308106
[TBL] [Abstract][Full Text] [Related]
5. How many physicians does Canada need to care for our aging population?
Roos NP; Bradley JE; Fransoo R; Shanahan M
CMAJ; 1998 May; 158(10):1275-84. PubMed ID: 9614820
[TBL] [Abstract][Full Text] [Related]
6. Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti-viral drugs as an example.
Rawson NS
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1072-9. PubMed ID: 19650154
[TBL] [Abstract][Full Text] [Related]
7. Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: a descriptive study.
Yoong D; Bayoumi AM; Robinson L; Rachlis B; Antoniou T
CMAJ Open; 2018; 6(4):E551-E560. PubMed ID: 30482757
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.
Campbell DJT; Manns BJ; Soril LJJ; Clement F
CMAJ Open; 2017 Nov; 5(4):E808-E813. PubMed ID: 29180377
[TBL] [Abstract][Full Text] [Related]
9. Vasculometabolic effects in patients with congenital growth hormone deficiency with and without GH replacement therapy during adulthood.
Biscotto IP; Costa Hong VA; Batista RL; Mendonca BB; Arnhold IJP; Bortolotto LA; Carvalho LRS
Pituitary; 2021 Apr; 24(2):216-228. PubMed ID: 33098037
[TBL] [Abstract][Full Text] [Related]
10. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.
Demers V; Melo M; Jackevicius C; Cox J; Kalavrouziotis D; Rinfret S; Humphries KH; Johansen H; Tu JV; Pilote L
CMAJ; 2008 Feb; 178(4):405-9. PubMed ID: 18268266
[TBL] [Abstract][Full Text] [Related]
11. State of provincial regulations and guidelines to promote low impact development (LID) alternatives across Canada: Content analysis and comparative assessment.
Ishaq S; Hewage K; Farooq S; Sadiq R
J Environ Manage; 2019 Apr; 235():389-402. PubMed ID: 30708276
[TBL] [Abstract][Full Text] [Related]
12. Inter-provincial variation in government drug formularies.
Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
[TBL] [Abstract][Full Text] [Related]
13. Use of product listing agreements by Canadian provincial drug benefit plans.
Morgan SG; Friesen MK; Thomson PA; Daw JR
Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
[TBL] [Abstract][Full Text] [Related]
14. Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan's syndrome and effects of GH replacement therapy.
Golgeli A; Tanriverdi F; Suer C; Gokce C; Ozesmi C; Bayram F; Kelestimur F
Eur J Endocrinol; 2004 Feb; 150(2):153-9. PubMed ID: 14763913
[TBL] [Abstract][Full Text] [Related]
15. Effects of aerobic exercise on ectopic lipids in patients with growth hormone deficiency before and after growth hormone replacement therapy.
Christ ER; Egger A; Allemann S; Buehler T; Kreis R; Boesch C
Sci Rep; 2016 Jan; 6():19310. PubMed ID: 26792091
[TBL] [Abstract][Full Text] [Related]
16. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
Coombes ME; Morgan SG; Barer ML; Pagliccia N
Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
[TBL] [Abstract][Full Text] [Related]
17. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
Kennedy J; Morgan S
Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
[TBL] [Abstract][Full Text] [Related]
18. Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.
Beckers D; Thomas M; Jamart J; Francois I; Maes M; Lebrethon MC; De Waele K; Tenoutasse S; De Schepper J
Eur J Endocrinol; 2010 Mar; 162(3):483-90. PubMed ID: 19969557
[TBL] [Abstract][Full Text] [Related]
19. Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy.
Rizzo M; Trepp R; Berneis K; Christ ER
Eur J Endocrinol; 2007 Mar; 156(3):361-7. PubMed ID: 17322496
[TBL] [Abstract][Full Text] [Related]
20. Predictive risk modelling of high resource users under different prescription drug coverage policies in Ontario and Manitoba, Canada.
Kornas K; Sarkar J; Fransoo R; Rosella LC
BMC Health Serv Res; 2023 Jul; 23(1):768. PubMed ID: 37468878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
